



**FACTORS ASSOCIATED WITH NOSOCOMIAL FUNGAL
SEPSIS AMONG PATIENTS IN THE PAEDIATRIC
INTENSIVE CARE UNIT AT THE CHRIS HANI
BARAGWANATH ACADEMIC HOSPITAL**

Seung-Hye Ahn

A research report submitted to the Faculty of Health Sciences, University of the
Witwatersrand, Johannesburg in partial fulfillment of the requirements for the degree of
Master of Medicine in the branch of Paediatrics and Child Health

29 May 2017

DECLARATION

I, Seung-Hye Ahn, declare that this research report is my own work. It is being submitted for the degree of Master of Medicine in the branch of Paediatrics and Child Health, to the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at this or any other university.

A handwritten signature in black ink, appearing to read 'Seung-Hye Ahn', written in a cursive style.

Seung-Hye Ahn

On the 29th day of May 2017

DEDICATION

First and above all, I praise God my Father for granting me the capability and wisdom to proceed and complete this project. I dedicate this work to my husband, Jin-Gu Kim who has been my constant source of support and encouragement, and to my family and Reverend Bong-Suk Oh's family for their unconditional love and prayers.

ABSTRACT

Introduction

Sepsis, and in particular, severe sepsis, remains a major cause of death in children worldwide. One of the areas where the burden of sepsis is keenly felt is in the paediatric intensive care unit (PICU) setting, contributing significantly to childhood mortality. Fungal organisms have emerged as a major organism contributing to nosocomial sepsis in PICU. No local data regarding nosocomial fungal sepsis in the non-neonatal, PICU population exists regarding this matter. This study describes the characteristics of patients with nosocomial fungal sepsis in the PICU at South Africa's largest hospital Chris Hani Baragwanath Academic Hospital (CHBAH).

Methods

This study was a retrospective review of patient records. All patients aged 0-16 years admitted to the PICU at Chris Hani Baragwanath Academic Hospital (CHBAH) from January 2008 through December 2011 were assessed. A total of seventeen patients who developed nosocomial fungal sepsis were included in this study.

Results

The incidence of candidaemia was reported to be 3.2 per 100 cases. The major age group affected by nosocomial fungal sepsis was the under one age group. The most common diagnoses on admission were lower respiratory tract infection (LRTI) followed by haematology-oncology and acute gastroenteritis cases. ICU factors found to commonly co-exist with proven nosocomial fungal sepsis were presence of a central venous

catheter (100%), mechanical ventilation (82%), arterial line (70%), and systemic corticosteroid use (47%). The penicillin class was the most common antimicrobial that patients were found to be on at the time of nosocomial sepsis. The most common fungal organism as a cause for nosocomial sepsis was *C. parapsilosis* rather than *C. albicans*. Furthermore, the majority of this study's isolates were susceptible to voriconazole rather than the current empiric antifungal of choice, namely fluconazole.

Conclusion

The presence of central venous catheters, arterial lines, mechanical ventilation and systemic corticosteroid use is common in paediatric patients with nosocomial fungal sepsis. However, this study was unable to determine statistically significant factors associated with fungal sepsis in a tertiary PICU due to the surprisingly small number of cases (n=35) detected over a four-year period. This perhaps represents the most striking finding of the study together with a concerning pattern of fluconazole resistance (14%) among isolated organisms.

ACKNOWLEDGEMENTS

I would like to express my deepest appreciation to my supervisor Dr Kuban Dhasaradha Naidoo, for his full support, expert guidance, encouragement and most importantly his patience throughout the entire process of this research work.

I would also like to thank the Main ICU staff at CHBAH, namely Ms. Mpho Nkobe and Ms. Mapule Mathonzi for sacrificing their time and assisting me in retrieving all necessary patient records.

TABLE OF CONTENTS	Page
DECLARATION	ii
DEDICATION	iii
ABSTRACT	iv
Introduction	iv
Methods	iv
Results	iv
Conclusion	v
ACKNOWLEDGEMENTS	vi
TABLE OF CONTENTS	vii
LIST OF TABLES	x
LIST OF FIGURE	xi
ABBREVIATIONS	xii
CHAPTER ONE	1
1.0 INTRODUCTION	1
1.1 Background	1
1.2 Microbial aetiology of sepsis in the PICU	2
1.3 Nosocomial fungal sepsis	3
2.0 BASIC MYCOLOGY OF CANDIDA	4
2.1 PATHOGENESIS OF CANDIDA SPECIES	5
2.1.1 Adherence and biofilm formation	6

2.1.2 Host Tissue Damage By Hydrolytic Enzyme Production	7
2.2 RISK FACTORS FOR NOSOCOMIAL CANDIDA BLOODSTREAM INFECTION	7
2.2.1 Host factors	8
2.2.2 Environmental factors	10
2.3 DIAGNOSIS OF CANDIDA BLOODSTREAM INFECTION	11
2.4 TREATMENT OF CANDIDA BLOODSTREAM INFECTION.....	13
2.5 MORTALITY ASSOCIATED WITH BLOODSTREAM INFECTION.....	15
2.6 WHAT THIS STUDY ADDS	16
CHAPTER TWO	17
2.1 OBJECTIVES	17
2.2 METHODS	17
2.2.1 Study Design	17
2.2.2 Study population	17
2.2.3 Definition of Case Patients	18
2.2.4 Data Collection	18
2.2.5 Statistical Analysis	19
2.2.6 Ethical considerations	19
CHAPTER THREE	20
3.0 RESULTS	20
3.1 Incidence	20
3.2 Characteristics	20
3.3 Admission Diagnoses	21

3.4 Fungal Isolates	23
3.5 Susceptibilities	23
3.6 ICU related factors	24
CHAPTER FOUR.....	26
4.0 DISCUSSION	26
4.1 Incidence	26
4.2 Patient Demographics	27
4.3 Admission Diagnoses	28
4.4 Organisms	29
4.5 Organism Susceptibility	30
4.6 ICU factors	31
4.7 Potential limitations	35
5.0 CONCLUSION	36
REFERENCES	37
APPENDIX A – Reference Values.....	51
APPENDIX B – Data Collection Tool	52
APPENDIX C – Ethics Clearance Certificate	53
APPENDIX D – Hospital Permission Letter	54
APPENDIX E – Turnitin Report	55

LIST OF TABLES

Page

3.1	21
3.2	22
3.3	24
3.4	25

LIST OF FIGURE

3.1	23
-----------	----

ABBREVIATIONS

ALL	Acute Lymphoblastic Leukaemia
AML	Acute Myeloid Leukaemia
BDG	(1,3)- β -D-glucan
BSI	Blood Stream Infections
CA	Candida albicans
CHBAH	Chris Hani Baragwanath Academic Hospital
CVC	Central Venous Catheter
ELISA	Enzyme-linked Immunosorbent Assay
EPA	Epithelial Adhesin
FDA	Food and Drug Administration
HIV	Human Immunodeficiency Virus
LRTI	Lower Respiratory Tract Infection
NAC	Non-albicans Candida
NHLS	National Health Laboratory Services
PCR	Polymerase Chain Reaction
PICU	Paediatric Intensive Care Unit
SD	Standard Deviation
SDB	Sabouraud Dextrose Broth
SIRS	Systemic Inflammatory Response Syndrome
TPN	Total Parenteral Nutrition
US	United States
WHO	World Health Organization

CHAPTER ONE

1. INTRODUCTION

1.1 Background

Sepsis, and in particular, severe sepsis, remains a major cause of death in children worldwide. (1-3) Sepsis is defined as a systemic inflammatory response syndrome (SIRS) in the presence of or as a result of a suspected or proven infection. (4) This definition, including the definitions for the continuum of sepsis was defined for the paediatric population by the International Pediatric Sepsis Consensus Conference in 2002. These include definitions for infection, SIRS, sepsis, severe sepsis and septic shock, which are summarized in appendix A.

The World Health Organization (WHO) reported infectious diseases as the number one killer of children under the age of five years, causing 68% of deaths in this age group in 2008. (5) One of the areas where the burden of sepsis is keenly felt is in the paediatric intensive care unit (PICU) setting, contributing significantly to childhood mortality. (6,7) A Japanese study reported PICU mortality of 28% in patients diagnosed with septic shock between 2007 and 2009. An Italian study reported a staggering 51% mortality rate among children with septic shock in the PICU. (8) Likewise, high mortality rates due to septic shock were also reported in Pakistan, affecting approximately a third (32,8%) of the population admitted to the PICU from 2007 through 2008. (9)

With such a significant burden to childhood mortality, extensive research is aimed at improving the diagnosis and management of sepsis. (1,4,10,11) However despite these efforts, studies continue to demonstrate a rise in the incidence of severe sepsis. A 1995

population-based study investigating severe sepsis reported an incidence in excess of 42,000 new cases among American children. (3) Further epidemiological data from the United States (US) reported a staggering increase in the incidence of sepsis from 82.7 per 100,000 population to nearly 240.4 per 100,000 population over a 21-year period between 1979 and 2000. (6)

Not only does severe sepsis impact dramatically on childhood morbidity and mortality, it also poses a significant healthcare problem due to the extensive usage of healthcare resources. The attributable annual cost to the US health-care system in 1995 was 1.97 billion US dollars, which more than doubled to 4.8 billion US dollars per annum over the subsequent ten year period. (12) With sepsis attributing heavily to childhood mortality both in developed and developing countries, as well as heavily burdening health-care costs, extensive research is required in determining the cause, pathophysiology and management of sepsis in PICU. (10)

1.2 Microbial aetiology of sepsis in the PICU

The three most common microbial groups causing sepsis in the PICU are Gram-positive bacteria, Gram-negative bacteria and fungi. (13-15) In the mid 1990's the most common infecting organisms were *Staphylococcus* species, however by 2005 it had become apparent that Gram-negative organisms were responsible for a large proportion of severe sepsis cases in the PICU. (3,14,15) The most common Gram-negative pathogens were *Pseudomonas aeruginosa* and *Enterococcus faecalis* in a Japanese and Brazilian study, respectively. (14,15) This evolving face of microbial epidemiology was also noted in North America where a significant increase in organisms other than bacteria, such as

fungal infections was noted over a 22-year period. *Candida* species (responsible for the vast majority of fungal infections) has been reported as the fourth most common pathogen responsible for nosocomial (hospital-acquired) sepsis. (6,16)

1.3 Nosocomial fungal sepsis

A few decades ago, fungi were uncommon nosocomial pathogens. (17) However, since 1979 fungi have emerged as important pathogenic organisms among patients with nosocomial sepsis. (18,19) The last two decades of the twentieth century saw a staggering 207% increase in new cases of fungal sepsis. (6) Italian researchers found that the incidence of candidaemia had more than doubled among critically ill patients around the turn of the century. (20)

Among fungal organisms, *Candida* species are the most common organisms responsible for fungal bloodstream infections (BSI). (16,21) Overall, they are the fourth most common isolate in nosocomial BSI and the third most common cause of nosocomial BSI in critically ill patients. (16,22,23) Consistent with the overall increase in fungal infections, the incidence of nosocomial candidaemia has also risen rapidly over the past two decades. (6,24-26) A five-fold increase of candidaemia from 0.06 to 0.3 per 1,000 inpatients was observed between 2000 and 2009 in the US. (25) Of note, the rate of nosocomial candidaemia among the non-neonatal paediatric population doubled during a 9 year period between 1997 and 2005. (24)

Candida species can be broadly classified into two groups namely *Candida albicans*

(CA) and the non-*albicans Candida* (NAC). Over recent years, despite the emergence of NAC species causing disease, CA remains the most common fungus to cause bloodstream infections in the paediatric population, accounting for 40-60% of cases. (24,27-32)

2.0 BASIC MYCOLOGY OF CANDIDA

The genus *Candida* is classified as follows:

- Kingdom: Fungus
- Phylum: Ascomycota
- Subphylum: Saccharomycotina
- Class: Saccharomycetes
- Order: Saccaromycetales and
- Family: Saccharomycetaceaea. (33)

Candida colonies appear cream to yellow macroscopically and are typically grown on Sabouraud dextrose agar. Colony texture may differ according to the species and may be smooth, dry or wrinkled. Growth occurs as blastoconidia, which are spherical to oval shaped budding cells. (34) Certain morphological features help in distinguishing between *Candida* species such as branch-like extensions from the budding cell, otherwise known as true hyphae or pseudohyphae. (35) True hyphae and/or pseudohyphae are diagnostic features of *C. albicans*. In contrast, *C. glabrata* lack the ability to grow hyphae and exist as ovoid blastoconidia. (34,35) Other distinguishing features include the size of blastoconidia of which *C. glabrata* measures the smallest (1-4 μm) and the largest species

C. albicans (4–6 µm) and *C. tropicalis* (4–8 µm). (36)

The *Candida* genus contains over 150 species of which a minority (13 species) have been implicated in the pathogenesis of disease in humans. The most common of these are *C. albicans* and among the NAC species, *C. glabrata*, *C. krusei*, *C. parapsilosis*, and *C. tropicalis*. (21,24,28) Furthermore, approximately two thirds of *Candida* species are unable to grow at temperatures around 37°C rendering them unable to successfully dwell and colonize human hosts. (35)

Candida species usually exist as human commensals as part of the normal flora found on the skin, oropharyngeal cavity, gastrointestinal tract and vaginal tract. (37) *Candida* can also be found on other mammals, birds, arthropods, fish, plants, as well as soil, water and airborne particles. (38) Pathogenicity of *Candida* is initiated once the immune defenses of the host have been compromised and/or following events resulting in a disruption or imbalance of the host's normal commensal flora. (37)

2.1 PATHOGENESIS OF CANDIDA SPECIES

Broadly speaking, the pathogenicity of *Candida* species can be attributed to two primary virulence factors:

1. adherence and biofilm formation on host tissue and medical devices
2. host tissue-damage by the production of hydrolytic enzymes such as phospholipases, proteases and haemolysins. (34,39)

2.1.1 Adherence and biofilm formation

Adherence to host tissue is the initial step for *Candida* species to ensure persistence of the organism within the host, which ultimately leads to the establishment of disease. Specific cell wall proteins (adhesins), allow *Candida* to adhere to human tissue as well as to other surfaces such as medical devices. (34) These adhesin proteins are encoded by different gene families, depending on the specific *Candida* species. (34)

C. glabrata's adhesins are encoded by the gene family EPA (epithelial adhesin) and have the ability to adapt to a wide variety of environmental conditions. (40) The advantage conferred to the organisms by this adaptability results in an improved ability to adhere to, and subsequently colonise host tissue.

Once adherence to the host tissue has been established, *Candida* species undergo the processes of cell division and proliferation, in order to produce a population of microorganisms incorporated within an extracellular matrix (biofilm). (41) The biofilm, by virtue of its solid matrix, is able to resist the host immune responses and minimize the penetration of antifungal substances. (42) Thus the biofilm contributes significantly to the outcome of patients who have established fungal disease. The attributable mortality rate in patients with bloodstream infections caused by biofilm-positive organisms compared to those without biofilm formation was reported to be as high as 30%. (43)

The formation of a biofilm is influenced both by the *Candida* species, as well as the environment to which the organism is exposed. (41) In particular, *C. albicans* isolates

produce quantitatively and qualitatively superior biofilm matrices in substrate similar to indwelling devices, when compared to NAC species such as *C. parapsilosis*, *C. glabrata* and *C. tropicalis*. (44) In contrast, *C. albicans* produced the least amount of biofilm on Sabouraud dextrose broth (SDB) containing 8% glucose (similar to milieu of patients receiving total parenteral nutrition via a central venous catheter) compared to *C. tropicalis* followed by *C. parapsilosis*. (43,45) Furthermore, *C. glabrata* was reported as the most frequent organism forming biofilms on indwelling catheters in the presence of urine. (46)

2.1.2 Host Tissue Damage By Hydrolytic Enzyme Production

Host tissue destruction may be expedited by the release of hydrolytic enzymes produced by *Candida* species. The most frequently encountered enzymes are secreted aspartyl proteinases, phospholipases, lipases and haemolysins. (34)

Secreted aspartyl proteinases contribute to pathogenicity by digesting mucosal membranes and molecules of the host immune system. (34) Phospholipases and lipases are involved in the hydrolysis of fatty acids and triacylglycerol components of host cells. (34) *C. albicans* strains, in particular, show significant extracellular phospholipase activity which contributes to the enhanced virulence of this species. (47)

2.2 RISK FACTORS FOR NOSOCOMIAL CANDIDA BLOODSTREAM INFECTION

Knowledge of the population at risk for nosocomial *Candida* BSI is imperative for further preventative measures and empiric treatment of the disease. Risk factors can be broadly grouped into defects of host's immunity and effects from the external

environment increasing the probability of acquiring a *Candida* BSI.

2.2.1 Host factors

Once host immune defences have been compromised, *Candida* species, which formerly existed as human commensals, are able to invade, populate and exert its detrimental effects on the host. Paediatric immunocompromised states described in the literature include immunodeficiency disease, malignancy, neutropaenia, bone marrow transplantation, undergoing surgery, critical illness, prematurity, very-low-birth-weight and congenital anomalies. (28)

In particular, South Africa still carries the highest burden of people living with HIV (6,1 million of the global 35,3 million global estimates) at the end of 2012. (48) Of the 6,1 million affected individuals in South Africa, children from zero to fourteen years of age account for 6,7% (410,000) of South Africa's total. (49) Data from the Chris Hani Baragwanath Hospital paediatric medical wards showed an approximate 10-fold increase in the prevalence of HIV infected individuals from 1992 to 1997. (50) Furthermore, in the same period the study reported a longer length of stay, higher readmission rate and a staggering 42% increase in the in-hospital mortality of patients infected with HIV compared to the non-HIV population. (50)

With regards to PICU and HIV, a first-world study in the late 1980's showed case fatality rates of up to 84% in HIV-infected children requiring intensive care. (51) Offering intensive care to this population in a resource poor country such as South Africa remains a difficult decision. (52) However, South African studies that were conducted in 2003 and 2009 have seen a decline in mortality rate of 30% and an increased survival rate up to

64% in the HIV-infected admissions to PICU. (52,53) A possible reason for the improved survival rate could be attributed to the rollout of Highly Active Antiretroviral Treatment to HIV-infected children. (54) With prolonged survival of this HIV-infected population, fungal infections have begun to emerge as a key organism in causing morbidity and mortality in the immunocompromised host. (28,55)

Candida species remain one of the most common opportunistic infections in children infected with HIV. (55,56) In the late 90's, a European study among HIV infected individuals reported *C. albicans* as the most frequently isolated pathogen, followed by *C. tropicalis* and *C. glabrata*. (57) It is the response of the host's immune system, which determines the extent of *Candida* pathogenicity. Manifestations of *Candida* infection have been described as benign oral mucosal overgrowth to widespread haematogenous dissemination causing organ compromise in the host. (55)

Invasive fungal infections are also an important cause of morbidity and mortality among neutropenic patients. (58) A 2015 retrospective analysis in Turkey showed a 3.1 fold increase in mortality among patients with neutropenia and Candidaemia. (59) Radiation, chemotherapy, bone marrow failure, or the replacement of hematopoietic cells in the bone marrow by malignant cells, are the main causes of neutropenia. (60) Neutropenia in itself is a significant risk factor for the development of systemic Candida disease. (60) The main portal of entry is via the alimentary tract and when disrupted, invasion to the main bloodstream ensues. (60) Candida infection manifestations range from oropharyngeal candidiasis, oesophageal candidiasis, candidaemia, acute disseminated candidiasis or chronic disseminated candidiasis. (60)

2.2.2 Environmental factors

Environmental risk factors described are as follows:

- endotracheal intubation with mechanical ventilation
- central venous lines
- arterial lines
- urinary catheter
- hypoalbuminaemia
- male gender
- neutropaenia
- total parenteral nutrition (TPN)
- prolonged ICU stay
- broad-spectrum antibiotics
- bacterial infections
- corticosteroids
- blood transfusions and
- peritoneal or haemodialysis. (24,26-28,59)

Specifically, two factors were independently associated with the development of candidaemia in the PICU, namely the presence of a central venous catheter (CVC) and the receipt of a glycopeptide antibiotic (Vancomycin) or antimicrobial activity against anaerobic organisms for more than three days. (27) A study in 2015 showed a 20.5 fold increase in mortality due to failure of removal of a CVC in patients with candidaemia.

(59)

The first line of defense in the human body against infections is the presence of physical barriers, such as the skin and other epithelial surfaces, to prevent the entry of foreign micro-organisms. CVC's penetrate these natural barriers of the body and allow for the invasion of *Candida* species into otherwise sterile sites. (28,31) CVC placement for three days or longer, has been associated with a three-fold risk for developing disseminated candidiasis in children with candidaemia. (61)

The glycopeptide antibiotic Vancomycin has activity against anaerobic bacteria in the gastrointestinal tract. (27) Under normal circumstances anaerobic gut flora contribute to the host's defense mechanisms by minimizing the growth of potentially pathogenic organisms such as *Candida* species. By eliminating this protective mechanism by the usage of antimicrobials, the probability for *Candida* species to colonize the gastrointestinal tract, and then subsequently invade the host, rises. (27)

Host and environmental factors frequently co-exist, especially in the PICU setting where critically ill patients with varying degrees of immunosuppression are exposed to multiple invasive procedures.

2.3 DIAGNOSIS OF CANDIDA BLOODSTREAM INFECTION

The definitive diagnosis of *Candida* BSI has represented a daunting challenge to both the clinician and the microbiologist. (62) Traditionally, the gold standard for the diagnosis of fungaemia has been isolation of the organism by blood culture from a normally sterile site. (62,63) Identification of yeasts is by carbohydrate assimilation and/or fermentation together with their macroscopic and microscopic morphologic features after growth on specialized culture media. (63) Disappointingly, the sensitivity of blood culture has

remained at a paltry 50%. This sensitivity is further compromised by technical errors such as use of non-sterile sites, insufficient blood sample volume and inadequate incubation time. Samples drawn from a non-sterile site make it virtually impossible to distinguish between colonization and invasive disease. Furthermore, due to the sluggish growth of yeast, the timeous initiation of antifungal therapy may be delayed, so much so, that the decision to start antifungal therapy is often an empiric one. (62,63)

Due to the poor yield of blood culture for the diagnosis of fungaemia, other tests using non-culture based tools have been developed and are currently used in conjunction with conventional blood culture methods. These tests include the (1,3)- β -D-glucan assay (BDG), fungal DNA using polymerase chain reactions and antibody assays.

Detection of a fungal cell wall component namely (1,3)- β -D-glucan (BDG) has been approved by the Food and Drug Administration of the US (FDA) as a diagnostic adjunct for invasive fungal disease including *Candida* species. (62) Being a fungal cell wall constituent, BDG can be used to detect the presence of most fungal species except for zygomycetes and *Cryptococcus* (63) The benefits of BDG as a biomarker when excluding invasive *Candida* infection was demonstrated by its negative predictive value of almost 99%. (64) However, false-positives are also common and measurement of BDG may be affected by exposure to glucan-containing gauze, intravenous administration of albumin, haemodialysis or Gram-positive bacteraemia such as *Streptococcus*. (62,65) It has been reported that certain Gram-positive bacteria such as *Streptococcus* and *Alcaligenes* also produce glucan-like polymers, which may falsely elevate the BDG levels. (66)

A rapid and more sensitive test using the polymerase chain reaction (PCR) method for the identification of *Candida* is being utilized more frequently in the PICU setting. (67) Isolates can be identified within 7 hours when compared to conventional phenotypic methods taking up to 48 to 72 hours long. (67)

Detection of antibodies against *Candida albicans* germ tubes has also been described. (63) However most critically ill patients may be unable to mount an adequate immune response, thus rendering tests utilizing the detection of antibodies as potentially ineffective. More specific markers of fungal components such as the cell wall and cytoplasmic antigens have provided an alternative means of providing a diagnosis. (63)

Attention has also been drawn to other potential biomarkers associated with the presence of fungal disease. The presence of thrombocytopenia has been used as a marker for sepsis in critically ill patients. (68) Studies in the neonatal population have shown an association between thrombocytopenia and fungal sepsis. (69-71) However scarce data exists for the non-neonatal paediatric population and further investigation into this phenomenon may be helpful in identifying patients at high risk of having a *Candida* BSI.

2.4 TREATMENT OF CANDIDA BLOODSTREAM INFECTION

Treatment of *Candida* BSI relies on timely administration of antifungal therapy based on the polyene, azole or echinocandin families. (32,72) Choice of antifungal therapy must be based on knowledge of local epidemiology, organism susceptibility, exposure to previous antifungal agents and the patient's clinical status.

The polyene antifungal (Amphotericin B) has been the most commonly used agent in the treatment of candidaemia, owing to its broad-spectrum activity. (73-75) However, the conventional Amphotericin B deoxycholate is known for its dose-limited toxicity, of which nephrotoxicity has been most frequently described. (74,76) Amphotericin B is a fungicidal agent disrupting the cell membrane by binding to ergosterol. Subsequently pores are formed in the membrane causing it to become leaky and depolarize. (77) In an attempt to improve the therapeutic index and provide a safer alternative, three forms of the agent were developed. These lipid-containing forms are amphotericin B lipid complex, liposomal amphotericin B, and amphotericin B colloidal dispersion. (74) Currently, the high cost of these lipid-containing forms does not make them widely accessible in a resource-limited setting such as the Chris Hanu Baragwanath Academic Hospital (CHBAH). However as the cost declines the newer forms of Amphotericin B will most likely play a significant role in the treatment of Candida BSI. (74) Despite its broad-spectrum activity and minimal intrinsic and acquired resistance, owing to its dose-limited toxicity, the polyene class is still limited in treatment when compared to the azoles and echinocandins. (77)

The azoles (fluconazole, voriconazole) are also a widely used antifungal drug with no nephrotoxic effects as compared to Amphotericin B. (77) This class inhibits cytochrome P-450 dependent enzyme C-14 α -demethylase. This enzyme is essential in the conversion of lanosterol to ergosterol, which forms part of the fungal cell membrane. (77) Despite its' low cytotoxicity, this class also displays significant limitations, namely: the development of resistance with prolonged use and drug-drug interactions, specifically drugs metabolized by the cytochrome P-450 isoenzyme. (78,79)

The echinocandins (caspofungin) are an emerging class of antifungal agents. FDA approval for Caspofungin was granted in 2001. Echinocandins inhibit cell wall synthesis by inhibiting the enzyme BDG-synthase, an essential component for wall synthesis. (78) Caspofungin was found to be as effective as amphotericin B, while exhibiting fewer drug-related side effects and a 72% favourable response over the standard amphotericin B group in the treatment of invasive candidiasis. (79,80)

Caspofungin, fluconazole, an amphotericin B formulation or combination therapy have been suggested by recent guidelines for the treatment of invasive candidiasis. (72) Other studies have suggested caspofungin and amphotericin B as first line therapies in neutropenic and critically ill patients where fluconazole-resistant *Candida* isolates may predominate. (79) However, patient therapy needs to be targeted and individualized to provide the most cost effective, therapeutic and least toxic treatment to the critically ill paediatric patient. (72,79)

2.5 MORTALITY ASSOCIATED WITH CANDIDA BSI

Mortality due to candidaemia in hospitalised patients remains high. (81-83) Mortality rates of approximately 60% were reported in observational studies, owing to nosocomial *C. albicans* sepsis. (24,75,82,83) This could be due to *C. albicans*'s enhanced virulence by destroying host tissue through phospholipases. (47) However, non-*albicans* species are seen to be on the rise as significant causes of mortality, especially in the premature and immunosuppressed populations. (25,84)

This mortality is found to be increased due to other environmental factors shown in recent studies investigating risk factors for mortality in candidaemic pediatric patients. (59,85) A 2016 Brazilian study found increase in mortality in patients with sepsis, septic shock, acute renal insufficiency, mechanical ventilation and dialysis. (85) In 2015, a Turkish study showed a significant result of a 23-fold increase in mortality of patients with candidaemia, (more than 3 months of age) where failure to remove CVC's were noted. (59)

Furthermore, mortality rates were affected by the timing of initiation of antifungal therapy. An American study carried out from 2002 to 2005 showed a ten percent increase in mortality rate for every day that antifungal therapy was delayed. (29) Consequences of failure to treat with antifungal therapy resulted in more than 25% of deaths over a four year period. (83)

2.6 WHAT THIS STUDY ADDS

This study aims to describe the characteristics of patients with nosocomial fungal sepsis in the PICU at South Africa's largest hospital CHBAH. There is overwhelming literature regarding fungal sepsis and the neonatal population however, a paucity of studies exists among the older pediatric population requiring intensive care. With the emergence of fungal sepsis as one of the leading causes of mortality in the PICU, an understanding of the risk factors may aid in the development of future guidelines for the empiric treatment of fungal nosocomial sepsis in the South African setting. This study is the first to be undertaken among a predominantly black non-neonatal paediatric population at a hospital serving a community with a high burden of HIV disease.

CHAPTER TWO

2.1 OBJECTIVES

The objective for this study was to describe the characteristics of patients who had developed a nosocomial fungal bloodstream infection in the PICU at the Chris Hani Baragwanath Academic Hospital.

The specific objectives were to:

1. Determine the incidence of fungal infections in the PICU
2. Describe the demographics of patients with nosocomial fungal bloodstream infections in the paediatric intensive care unit
3. Describe the PICU factors associated with nosocomial fungal bloodstream infections.

2.2 METHODS

2.2.1 Study design

This study was a retrospective descriptive study.

2.2.2 Study population

All patients aged 0-16 years, admitted to the PICU at Chris Hani Baragwanath Academic Hospital (CHBAH) from January 2008 through December 2011. CHBAH is an academic tertiary hospital situated in Gauteng province with 3200 beds of which 408 are paediatric beds. It currently serves Soweto and surrounding communities. The PICU consists of an

8-bed critical care unit that has an estimate of 360 annual admissions. All patients admitted to the PICU were identified using the PICU admissions database.

2.2.3 Definition of Case Patients

Case patients were patients who had developed a nosocomial fungal BSI. Nosocomial fungal BSI was defined by proven fungal species yielded on blood culture that was taken at least 48 hours after admission to PICU, in addition to the presence of SIRS. Case patients were identified from the microbiology database at the National Health Laboratory Services (NHLS). Once patients were identified, databases were retrieved from the PICU records department situated at the CHBAH.

Patients with incomplete records and infected simultaneously with fungal and non-fungal organisms on blood culture were excluded.

2.2.4 Data Collection

All blood cultures, which deemed a positive fungal growth between 2008 and 2011 were identified through an extensive search performed by an NHLS accredited data analyst. Names of patients were identified and files were retrieved from the CHBAH ICU records department.

A data collection tool, RedCap was used to collect patient data. (Appendix B). This data sheet included four sections namely: patient demographics, background, laboratory results and PICU-related factors.

Demographics dealt with patient sex and age at time of diagnosis. Background factors included primary condition, pre-ICU major operation (any surgery requiring general anaesthesia) and HIV status. Laboratory data collected included organism yielded on blood culture and drug susceptibility at the time of SIRS. ICU-related factors included devices (CVC, urinary catheter, arterial-line, intercostal chest drain, endotracheal tube and tracheostomy devices), dialysis (haemo-dialysis and peritoneal dialysis), class of antimicrobial therapy used for more than 24 hours, receipt of TPN, immunosuppressant usage and three or more blood product transfusions. ICU-related factors were selected by review of previous studies with similar objectives.

2.2.5 Statistical Analysis

For descriptive purposes, means, medians, ranges (min-max) and proportions (percentages) were reported for categorical variables.

2.2.6 Ethical considerations

Ethics approval was obtained from the Committee for Research in Human Subjects at the University of the Witwatersrand (Medical) and the Medical Advisory Committee of the Chris Hani Baragwanath Academic Hospital. Permission to conduct research was obtained from the director of the PICU at CHBAH. The National Health Laboratory Service granted permission to access patient data from the central database.

CHAPTER THREE

3. RESULTS

3.1 Incidence

There were a total of 1085 admissions to the CHBAH PICU from January 2008 to December 2011. Thirty-five patients (3%) with positive fungal blood cultures were identified during the four year period. Fourteen of the 35 files were missing from the data department and four patients did not fit the inclusion criteria. Thus, 17 cases were included in the study.

3.2 Characteristics

The demographics of the 17 eligible patients are summarized in table 3.1. The gender distribution was similar with 53% female (9/17) and 47% males (8/17). Patient age ranged from day 1 of life to 11 years 5 months with a median age of 10 months. Age distribution was compared among male and female groups. Males presenting at PICU had a higher median age (1 year 6 months) while females presented at a younger age (4 months). Among the patients with HIV results available (n=12, 70%), the vast majority was HIV negative (92%) with only one patient with confirmed fungal sepsis testing HIV positive. The remaining 5 patients (30%) did not have an HIV result available at the time of their PICU admissions.. The time from admission up to the time where fungal sepsis occurred, ranged broadly from two to 122 days (median =9).

Table 3.1 Characteristics of PICU patients who developed nosocomial fungal sepsis

Gender	
Male	8 (47%)
Female	9 (53%)
Age distribution (All patients)*	10m (1d-11y5m)
Male age distribution*	1y6m (1m-11y5m)
Female age distribution*	4m (1d-9y)
HIV status	
Negative	11 (65%)
Positive	1 (6%)
Unknown	5 (29%)
Pre-ICU operation	
Yes	5 (29%)
No	12 (71%)
Onset of sepsis from admission* (days)	9 (2-122)
* Median (range: min-max)	

3.3 Admission Diagnoses

The most common group of admission diagnoses was lower respiratory tract infections with nearly a third (29%) of patients admitted for either bronchopneumonia or a lobar pneumonia. A summary of the admission diagnoses is presented in table 3.2.


Table 3.2 Diagnoses of patients who developed nosocomial fungal sepsis

	n (%)
Respiratory	
Bronchopneumonia	3 (18%)
Lobar pneumonia	2 (12%)
Gastrointestinal	
Acute gastroenteritis (traditional medicine ingestion)	3 (18%)
Haematology-Oncology	
Acute lymphoblastic leukaemia (ALL)	1 (6%)
Acute myeloid leukaemia (AML)	1 (6%)
Osteogenic sarcoma	1 (6%)
Trauma	
Pedestrian vehicle accident	2 (12%)
Cardiovascular	
Congenital cardiac defect	1 (6%)
Urogenital	
Urinary tract infection	1 (6%)
Surgical	
Subphrenic abscess	1 (6%)
Intussusception	1 (6%)

3.3 Fungal isolates

The most common isolates from the paediatric intensive care unit were *Candida parapsilosis* (n=9), followed by *Candida albicans* (n=7).

Figure 3.1 Fungal isolates from blood culture in PICU



3.4 Susceptibilities

Susceptibilities were reported for 15 of the 17 (88%) fungal isolates. No susceptibilities were specified for *C. lusitanae* and one of the *C. albicans* isolates. The remaining fifteen organisms' susceptibility patterns are summarized in Table 3.3. Seventy five percent (3/6) of the *C. albicans* group was susceptible to fluconazole, an additional 16% (1/6) to voriconazole and all reported isolates remained sensitive to Amphotericin B (6/7). One of the six (17%) *C. albicans* isolates was resistant to both fluconazole and voriconazole. In the *C. parapsilosis* group, 22% were susceptible to fluconazole, 67% to voriconazole and all isolates

remained sensitive to Amphotericin B. One of the nine (11%) *C. parapsilosis* isolates was resistant to both fluconazole and voriconazole..

Table 3.3 Reported Susceptibility to Antifungals

Organism (n)	Fluconazole Sensitive	Voriconazole Sensitive	Amphotericin Sensitive
<i>C. parapsilosis</i> (9)	2 (22%)	6 (67%)	9 (100%)
<i>C. albicans</i> (6)	4 (67%)	5 (83%)	6(100%)

3.5 ICU related factors

All of the patients with nosocomial fungal sepsis were found to have central venous catheters in situ (100%). Fourteen of the 17 patients received mechanical ventilation (82%). The most common antimicrobial received during the time of onset of sepsis was penicillin (71%). The other ICU related factors and subsequent findings on steroid use, TPN and other associated factors are summarized in table 3.4, which was found to be present in less than 50% of the patients.

Table 3.4 ICU related factors in patients who developed nosocomial fungal sepsis

ICU related factors	n (%)
Central venous catheter	17 (100%)
Mechanical ventilation	14 (82%)
Arterial line	12 (70%)
Steroids	8 (47%)
Total parenteral nutrition	6 (35%)
Multiple blood product transfusions (>3)	5 (29%)
Intercostal chest drain	2 (12%)
Antimicrobial therapy:	
Penicillin	12 (71%)
Antifungal	9 (53%)
Carbapenem	7 (41%)
Glycopeptide	5 (29%)
Cephalosporin	4 (24%)
Aminoglycoside	3 (17%)

CHAPTER FOUR

4. 0 Discussion

Local studies regarding epidemiology and factors associated with nosocomial fungal sepsis in the PICU is scarce. Nosocomial fungal sepsis is becoming an increasingly important subject of research owing to its high contribution to morbidity and mortality.

The aim of this study was to determine the incidence of nosocomial fungal sepsis, and to describe the demographics and PICU related factors of these affected patients. Knowledge regarding the trends of fungal organism growth and its associated factors are beneficial to the clinician when initiating treatment. Results from the analysis are discussed in this chapter, in light of other published studies.

4.1 Incidence

The incidence of candidaemia in the CHBAH PICU is 3.2 cases per 100 admissions. Thirty-five candidaemias were diagnosed in 1,085 patients (32.3 episodes per 1,000 ICU patients). These results are comparable to developed countries where the incidence lies between 1,7 to 10 episodes per 100,000 patients. (86) Although South Africa is considered to be an economically growing country, it is still considered a developing country where healthcare resources remain a scarce commodity especially in the intensive care setting.

4.2 Patient Demographics

The median age of fungal bloodstream infections was 10 months, which is similar to the findings of PICU studies conducted in Taiwan and Egypt, which both reported a majority of cases of fungal infection among the under-one age group (31,86). This could possibly be due to the vulnerability of this younger age group to serious diseases. These findings are in contrast to two other studies, which found most subjects with candidaemia to be over one-year of age. (87,88) The first study, performed in India (2011) found most patients in the 1 to 15 year old age group. (88) The second study, a case-control study in Turkey (2010) investigating the risk factors for candida in PICU reported a median age of 7.5 yrs. (87)

Gender distribution was fairly similar with an insignificantly higher percentage of females (53%). These findings are different to other studies from developing and developed countries. Male predominance was found in the Egyptian PICU study where 56.7% were male and 43.3% female. (86) An American study also showed a slightly higher male predominance (55.4%) in candidaemia infections (25).

Despite the high HIV burden in South Africa, 65% of cases were HIV negative and only one child (six percent) was confirmed to be HIV positive, thus the association between HIV and fungal sepsis could not be explored further. Kumar et al found 3.3% (7/210) association of HIV positive children and fungal sepsis. (88)

Of concern however, is the high proportion of subjects with unknown HIV status (29%). Three of the five patients had a medical diagnosis and the remaining two were admitted from the trauma unit, having both been involved in pedestrian vehicle accidents. At Chris Hani Baragwanath Academic Hospital, paediatric medical cases are referred from the general medical intake ward (ward 36). Here, patients are stabilized and relevant serological and radiological tests ordered prior to PICU referral. According to the hospital's paediatric policy, ward 36 is a crucial area where the patients' HIV status is either confirmed or investigated if unknown status. If the mother reveals that she is HIV positive during history-taking, an HIV-PCR is done on the patient provided the patient is under 18 months of age. If the patient is 18 months or older a confirmatory ELISA is taken and results followed up by the attending unit on call. However, if the mother reveals that she has been tested HIV negative, a confirmatory ELISA is done on the mother only and not on the patient. The three medical cases who had an "unknown" HIV status could possibly have had a mother who was HIV negative and a subsequent ELISA done on the mother, hence the actual HIV test not reflecting under the child's details. Or, the attending unit on call did not include an HIV test in their initial workup due to human error. The two trauma cases that were also of HIV "unknown" statuses are probably due to the trauma unit not requiring a mandatory HIV test on admission.

4.3 Admission Diagnoses

Admission diagnoses ranged across medical, surgical and trauma cases. Lower respiratory tract infections (LRTI) were shown to be the most common diagnosis among children with fungal nosocomial sepsis. A possible reason for patients with a LRTI

developing nosocomial fungal sepsis could be the prolonged stay in PICU due to their dependence on mechanical ventilation. The combination of prolonged exposure to nosocomial pathogens and contact with endotracheal tubing could form favourable conditions for the colonization and subsequent infection of nosocomial fungal pathogens (34).

Following LRTI's, haematology-oncology (18%) and acute gastroenteritis cases (18%) accounted for the second most common conditions with candidaemia. Similarly, an epidemiological study in Turkey also showed haematological malignancy as the second-most common underlying diagnosis. (24)

4.4 Organisms

C.albicans have accounted for the majority of Candida isolates among children during the 1990's and early 2000. (25-27,31) However from the mid 2000's an emergence of non-*Candida albicans* species, particularly *C. parapsilosis* was observed (89,90). These findings are similar to a Mexican study conducted in 2003 where *C. parapsilosis* attributed 52% in the pediatric population (90). This trend was also noted in a Spanish study showing a higher percentage of nosocomial infections due to *C. parapsilosis* (47%) and 37% due to *C. albicans* (62). Similarly, our study found *C.parapsilosis* as the predominant organism (53%) causing nosocomial fungal sepsis, followed by *C. albicans* (41%).

This rise in *C.parapsilosis* isolates can be attributed to three possible reasons. Firstly, poor infection control remains a major factor contributing to the spread of *C. parapsilosis*

despite the institution of ICU infection control programmes (24,91). An American study showed poor hand hygiene as an emerging cause of *C.parapsilosis* outbreaks in the neonatal ICU (91). Secondly, the organisms' ability to form biofilms in glucose containing media (eg. Parenteral nutrition) as well as its high propensity to adhere to medical devices may enhance its proliferation and survival in the human host in the PICU setting, where parenteral nutrition and intravascular catheters and other exogenous devices are common place. (34). Lastly, with the advent of newer techniques aiding in Candida species differentiation, the isolation of *C. parapsilosis* using CHROMagar ® has become more feasible (26, 36, 82)

4.5 Organism Susceptibility

Antifungal susceptibility and resistance patterns were documented in this study. This is the first study to provide this information in a local setting, thus allowing for improved empiric prescription in the PICU. Six of the 15 (40%) organisms showed susceptibility to fluconazole. This is strikingly different from an Iranian study, which showed 96.6% susceptibility to fluconazole (76). Additionally, this Iranian study showed both *C. albicans* and *C. parapsilosis* equally susceptible to fluconazole (76). However, our results showed the majority of isolates susceptible to fluconazole were *C. albicans* (67%).

In the *C. parapsilosis* group, a higher proportion was sensitive to voriconazole (67%) as opposed to fluconazole (22%). This is interesting of note as the unit's policy is to initiate fluconazole for suspected or proven fungal sepsis. Fluconazole is regarded as a favourable option as it is effective against most Candida species, has a low side-effect

profile and is also a cost-effective therapy (92). With the risk of fluconazole resistance among non-*Candida albicans* species, together with the higher incidence of *C. parapsilosis* in the CHBAH PICU, future policy recommendations could possibly be open for discussion within the unit (93). In view of these local findings, the initiation of voriconazole, instead of fluconazole could be a future recommendation in the empiric treatment of suspected nosocomial fungal sepsis at CHBAH PICU. However, in lieu of the small number of subjects, more research is needed in this field and prospective studies with a larger sample size are needed to confirm these findings.

4.6 ICU factors

Central venous catheters (CVC) were found in all the patients included in the study and arterial lines in 70% of patients with candidaemias. The CVC findings support the study done by Zaoutis et al, presenting CVC to be an independent risk factor for the development of candidaemia in PICU (27). A Turkish study in 2011 also found patients with candidaemia had higher rates of CVC. (87) A retrospective analysis in 2012 showed an alarming 23-fold increase in mortality due to failure of CVC removal. (59) Given that the placement of invasive vascular catheters is usually necessary in ICU patients, these findings emphasize the need for timely removal of such devices as a means to minimize the potential risk of nosocomial infections.

Furthermore, an American study showed a strong statistical significance between CVC's and *C. parapsilosis* (84). Central venous catheters introduce a portal of entry into the main vascular system and thus aiding the colonization and growth of opportunistic

infections (27). The placement of invasive catheters (CVC specifically) is routine in all patients admitted to PICU at CHBAH. It should be emphasized that their placement be performed under strictly sterile conditions, as their placement in critically ill patients poses a great risk in developing candidaemia. (27)

Among the ICU procedure category, mechanical ventilation also featured significantly in the study. Eighty-two percent of patients with nosocomial fungal sepsis were on mechanical ventilation. These findings are much higher than an American study showing 37% mechanically ventilated children (411 of 1118 hospitalized paediatric patients) who developed a nosocomial fungal infection. (27) A possible reason could be due to the limited resources and availability of ICU beds in South Africa, compared to first-world countries. This shortage means that patients who should be admitted earlier to PICU are kept in high care areas where treatment and ventilation may be sub-optimal, while awaiting an ICU bed. This delay could compromise the patient, resulting in a more severe phenotype of the presenting condition and possibly the development of a greater number of complications, which would thus necessitate a longer PICU stay.

Mechanical ventilation has been shown to be associated with candidaemia. (59,94) A case-control study showed a higher rate of mechanical ventilation in the candidaemia group. (94) Furthermore, Karadag-Oncel et al reported a 7.4-fold increased risk of mortality with candidaemia in mechanically ventilated patients. (59)

Lack of resources could also contribute to poor hygiene of equipment, re-usage of ventilation tubing and poor hand-washing contributing to prolonged ventilation. This study did not investigate how long it took for ventilated patients to develop nosocomial fungal sepsis so correlations between exposure and illness could not be drawn.

Corticosteroid usage has been described as a risk factor for nosocomial fungal sepsis (27,31,95). This has been hypothesized to the modulation of the immune system by corticosteroid therapy, crippling the patient's ability to prevent dissemination of candida infections (95). Almost half of the subjects in this study (47%) were documented to be on corticosteroid therapy at the time of nosocomial sepsis. However, the duration was not documented therefore no correlation between duration of treatment and development of nosocomial infections could be made.

Hyperalimentation has also been shown to be a suitable environment for the growth of Candida owing to its high glucose content (34). This study showed 35% of patients with a nosocomial fungal infection to have been on TPN. These findings are similar to Zaoutis et al's study mentioned above showing 33% of their patients having received hyperalimentation. (27) An American study showed exposure of parenteral nutrition for 12 days to be a risk factor for potential candidaemia in hospitalized patients . (26) Once again, the duration of exposure was not captured in this study so results from the aforementioned study could not be compared.

Broad-spectrum antibiotic use has been described as a risk factor for the development of nosocomial fungal sepsis (24,27,95). Antibiotic use has been shown to eliminate normal flora and thus encourage the colonization and growth of nosocomial organisms (96). This current study documented those patients who had received more than 24 hours of antibiotics and what class they had been on. Unfortunately the total duration of antibiotic exposure was not investigated so no comment regarding prolonged antibiotic use could be made.

In this study, the most frequently used antibiotic in the CHBAH PICU was of the penicillin group (71%). This high percentage of penicillin use could account for CHBAH's practice of prescribing either: ampicillin as the first-line antimicrobial for new admissions; or piperacillin-tazobactam used as a second-line option for a suspected nosocomial sepsis in the general paediatric ward. An American study found that patients receiving 3 or more days of vancomycin or an antimicrobial with anaerobic cover (piperacillin-tazobactam, Carbapenem, ceftriaxone, metronidazole, clindamycin etc), were independently associated with the development of nosocomial candidaemia in the PICU (61). Based on these findings, patients who are receiving piperacillin-tazobactam in CHBAH PICU should not be prescribed more than 3 days unless a specific indication exists, in the hopes of possibly decreasing the risk of developing a nosocomial fungal infection.

4.7 Potential limitations of the study

This study has potential limitations. As this study was a retrospective review of records, recruitment of patients relied solely on the adequacy of records. Many potential candidates were excluded from the study due to inadequate or absent records.

The lack of a control group was a great limitation in this study. Having a control group would have been beneficial as a comparison to substantiate and investigate further the associated risk factors in this study.

The small sample size made it difficult to find significant relationships within the data.

This small sample size could also give a false representation of patient distribution.

The data collection tool did not include duration of treatment such as corticosteroids, antimicrobials, ventilation etc. These factors could have assisted in exploring the relationships between treatment and development of nosocomial fungal sepsis.

5.0 CONCLUSION

This study is the first in South Africa investigating factors associated with nosocomial fungal sepsis at CHBAH PICU. The incidence is higher than what has been reported in some other studies. The majority of patients were less than a year of age and all the patients had CVC's. However this might have been due to the fact that it is a general practice for the unit to routinely insert CVC's. Although there was a predominance of *C. parapsilosis* that is susceptible to voriconazole, the study sample size was small and this needs to be further investigated to revise the empiric antifungal choice at the PICU at CHBAH.

REFERENCES

- (1) Anderson MR, Blumer JL. Advances in the therapy for sepsis in children. *Pediatr Clin North Am* 1997 Feb;44(1):179-205.
- (2) Hazelzet JA, Risseuw-Appel IM, Kornelisse RF, Hop WC, Dekker I, Joosten KF, et al. Age-related differences in outcome and severity of DIC in children with septic shock and purpura. *Thromb Haemost* 1996 Dec;76(6):932-938.
- (3) Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. The epidemiology of severe sepsis in children in the United States. *Am J Respir Crit Care Med* 2003 Mar 1;167(5):695-701.
- (4) Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. *Pediatr Crit Care Med* 2005 Jan;6(1):2-8.
- (5) Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. *Lancet* 2010 Jun 5;375(9730):1969-1987.
- (6) Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med* 2003 Apr 17;348(16):1546-1554.
- (7) Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 2001 Jul;29(7):1303-1310.

(8) Wolfler A, Silvani P, Musicco M, Antonelli M, Salvo I, Italian Pediatric Sepsis Study (SISPe) group. Incidence of and mortality due to sepsis, severe sepsis and septic shock in Italian Pediatric Intensive Care Units: a prospective national survey. *Intensive Care Med* 2008 Sep;34(9):1690-1697.

(9) Khan MR, Maheshwari PK, Masood K, Qamar FN, Haque AU. Epidemiology and outcome of sepsis in a tertiary care PICU of Pakistan. *Indian J Pediatr* 2012 Nov;79(11):1454-1458.

(10) Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. *Intensive Care Med* 2008 Jan;34(1):17-60.

(11) Santschi M, Leclerc F, members of the Reseau Mere-Enfant de la Francophonie. Management of children with sepsis and septic shock: a survey among pediatric intensivists of the Reseau Mere-Enfant de la Francophonie. *Ann Intensive Care* 2013 Mar 14;3(1):7-5820-3-7.

(12) Hartman ME, Linde-Zwirble WT, Angus DC, Watson RS. Trends in the epidemiology of pediatric severe sepsis. *Pediatr Crit Care Med* 2013 Sep;14(7):686-693.

(13) Wolfler A, Silvani P, Musicco M, Antonelli M, Salvo I, Italian Pediatric Sepsis Study (SISPe) group. Incidence of and mortality due to sepsis, severe sepsis and septic shock in Italian Pediatric Intensive Care Units: a prospective national survey. *Intensive Care Med* 2008 Sep;34(9):1690-1697.

(14) Shime N, Kawasaki T, Saito O, Akamine Y, Toda Y, Takeuchi M, et al. Incidence and risk factors for mortality in paediatric severe sepsis: results from the national paediatric intensive care registry in Japan. *Intensive Care Med* 2012 Jul;38(7):1191-1197.

(15) Porto JP, Mantese OC, Arantes A, Freitas C, Gontijo Filho PP, Ribas RM. Nosocomial infections in a pediatric intensive care unit of a developing country: NHSN surveillance. *Rev Soc Bras Med Trop* 2012 Jul-Aug;45(4):475-479.

(16) Wisplinghoff H, Seifert H, Tallent SM, Bischoff T, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. *Pediatr Infect Dis J* 2003 Aug;22(8):686-691.

(17) McGowan JE, Jr. Changing etiology of nosocomial bacteremia and fungemia and other hospital-acquired infections. *Rev Infect Dis* 1985 Jul-Aug;7 Suppl 3:S357-70.

(18) Morrison AJ, Jr, Freer CV, Searcy MA, Landry SM, Wenzel RP. Nosocomial bloodstream infections: secular trends in a statewide surveillance program in Virginia. *Infect Control* 1986 Nov;7(11):550-553.

(19) Pittet D, Wenzel RP. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. *Arch Intern Med* 1995 Jun 12;155(11):1177-1184.

- (20) Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, et al. Epidemiological trends in nosocomial candidemia in intensive care. *BMC Infect Dis* 2006 Feb 10;6:21.
- (21) Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. *Clin Infect Dis* 2005 Nov 1;41(9):1232-1239.
- (22) Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. *Intensive Care Med* 2002 Feb;28(2):108-121.
- (23) Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to *Candida albicans*: frequency of occurrence and antifungal susceptibility in the SCOPE Program. *Diagn Microbiol Infect Dis* 1998 May;31(1):327-332.
- (24) Celebi S, Hacimustafaoglu M, Ozdemir O, Ozkaya G. Nosocomial candidaemia in children: results of a 9-year study. *Mycoses* 2008 May;51(3):248-257.
- (25) Dutta A, Palazzi DL. *Candida non-albicans* versus *Candida albicans* fungemia in the non-neonatal pediatric population. *Pediatr Infect Dis J* 2011 Aug;30(8):664-668.
- (26) MacDonald L, Baker C, Chenoweth C. Risk factors for candidemia in a children's hospital. *Clin Infect Dis* 1998 Mar;26(3):642-645.

- (27) Zaoutis TE, Prasad PA, Localio AR, Coffin SE, Bell LM, Walsh TJ, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. *Clin Infect Dis* 2010 Sep 1;51(5):e38-45.
- (28) Filioti J, Spiroglou K, Panteliadis CP, Roilides E. Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. *Intensive Care Med* 2007 Jul;33(7):1272-1283.
- (29) Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. *Clin Infect Dis* 2006 Jul 1;43(1):25-31.
- (30) Steinbach WJ, Roilides E, Berman D, Hoffman JA, Groll AH, Bin-Hussain I, et al. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. *Pediatr Infect Dis J* 2012 Dec;31(12):1252-1257.
- (31) Chiu NC, Chung YF, Huang FY. Pediatric nosocomial fungal infections. *Southeast Asian J Trop Med Public Health* 1997 Mar;28(1):191-195.
- (32) De Rosa FG, Garazzino S, Pasero D, Di Perri G, Ranieri VM. Invasive candidiasis and candidemia: new guidelines. *Minerva Anesthesiol* 2009 Jul-Aug;75(7-8):453-458.
- (33) NCBI Taxonomy. Available at: <http://eol.org/pages/1013921/names>. Accessed 09/06, 2013.

- (34) Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. *Candida glabrata*, *Candida parapsilosis* and *Candida tropicalis*: biology, epidemiology, pathogenicity and antifungal resistance. *FEMS Microbiol Rev* 2012 Mar;36(2):288-305.
- (35) Calderone RA, Clancy CJ, editors. *Candida and candidiasis*. American Society for Microbiology Press; 2011 Dec 7.
- (36) Larone DH, Larone DH. *Medically important fungi: a guide to identification*. New York: Elsevier; 1987.
- (37) Naglik JR, Challacombe SJ, Hube B. *Candida albicans* secreted aspartyl proteinases in virulence and pathogenesis. *Microbiol Mol Biol Rev* 2003 Sep;67(3):400-28.
- (38) Barnett J, Payne R, Yarrow D. *Yeasts: Characteristics and Identification*. 2nd ed. Cambridge: Cambridge University Press; 1990.
- (39) Yang YL. Virulence factors of *Candida* species. *J Microbiol Immunol Infect* 2003 Dec;36(4):223-228.
- (40) Domergue R, Castano I, De Las Penas A, Zupancic M, Lockatell V, Hebel JR, et al. Nicotinic acid limitation regulates silencing of *Candida* adhesins during UTI. *Science* 2005 May 6;308(5723):866-870.
- (41) Ramage G, Wickes BL, Lopez-Ribot JL. Biofilms of *Candida albicans* and their associated resistance to antifungal agents. *Am Clin Lab* 2001 Aug;20(7):42-44.

- (42) Mukherjee PK, Chandra J. Candida biofilm resistance. *Drug Resistance Updates* 2004 0;7(4–5):301-309.
- (43) Tumbarello M, Posteraro B, Trecarichi EM, Fiori B, Rossi M, Porta R, et al. Biofilm production by *Candida* species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. *J Clin Microbiol* 2007 Jun;45(6):1843-1850.
- (44) Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofilms formed by *Candida albicans* and *Candida parapsilosis* on bioprosthetic surfaces. *Infect Immun* 2002 Feb;70(2):878-888.
- (45) Shin JH, Kee SJ, Shin MG, Kim SH, Shin DH, Lee SK, et al. Biofilm production by isolates of *Candida* species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. *J Clin Microbiol* 2002 Apr;40(4):1244-1248.
- (46) Silva S, Negri M, Henriques M, Oliveira R, Williams D, Azeredo J. Silicone colonization by non-*Candida albicans* *Candida* species in the presence of urine. *J Med Microbiol* 2010 Jul;59(Pt 7):747-754.
- (47) Mohan das V, Ballal M. Proteinase and phospholipase activity as virulence factors in *Candida* species isolated from blood. *Rev Iberoam Micol* 2008 Dec 31;25(4):208-210.
- (48) UNAIDS. AIDS by the numbers. 2013; Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2013/JC2571_AIDS_by_the_numbers_en.pdf. Accessed February 26, 2014.

(49) UNAIDS. South Africa. 2013; Available at:

<http://www.unaids.org/en/regionscountries/countries/southafrica/>. Accessed April/29, 2014.

(50) Zwi KJ, Pettifor JM, Soderlund N. Paediatric hospital admissions at a South African urban regional hospital: the impact of HIV, 1992-1997. *Ann Trop Paediatr* 1999 Jun;19(2):135-142.

(51) Vernon DD, Holzman BH, Lewis P, Scott GB, Birriel JA, Scott MB. Respiratory failure in children with acquired immunodeficiency syndrome and acquired immunodeficiency syndrome-related complex. *Pediatrics* 1988 Aug;82(2):223-228.

(52) Rabie H, de Boer A, van den Bos S, Cotton MF, Kling S, Goussard P. Children with human immunodeficiency virus infection admitted to a paediatric intensive care unit in South Africa. *J Trop Pediatr* 2007 Aug;53(4):270-273.

(53) Kitchin OP, Masekela R, Becker P, Moodley T, Risenga SM, Green RJ. Outcome of human immunodeficiency virus-exposed and -infected children admitted to a pediatric intensive care unit for respiratory failure. *Pediatr Crit Care Med* 2012 Sep;13(5):516-519.

(54) McConnell MS, Byers RH, Frederick T, Peters VB, Dominguez KL, Sukalac T, et al. Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001. *J Acquir Immune Defic Syndr* 2005 Apr 1;38(4):488-494.

(55) Muller FM, Groll AH, Walsh TJ. Current approaches to diagnosis and treatment of fungal infections in children infected with human immuno deficiency virus. *Eur J Pediatr* 1999 Mar;158(3):187-199.

(56) Alvaro-Meca A, Jensen J, Micheloud D, Diaz A, Gurbindo D, Resino S. Rate of candidiasis among HIV-infected children in Spain in the era of highly active antiretroviral therapy (1997-2008). *BMC Infect Dis* 2013 Mar 4;13:115-2334-13-115.

(57) Tumbarello M, Tacconelli E, de Gaetano Donati K, Morace G, Fadda G, Cauda R. Candidemia in HIV-infected subjects. *Eur J Clin Microbiol Infect Dis* 1999 Jul;18(7):478-483.

(58) Bow EJ. Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. *Semin Hematol* 2009 Jul;46(3):259-268.

(59) Karadag-Oncel E, Kara A, Ozsurekci Y, Arikan-Akdagli S, Cengiz AB, Ceyhan M, et al. Candidaemia in a paediatric centre and importance of central venous catheter removal. *Mycoses* 2015;58(3):140-148.

(60) Walsh TJ, Gamaletsou MN. Treatment of fungal disease in the setting of neutropenia. *Hematology Am Soc Hematol Educ Program* 2013;2013:423-427.

(61) Zaoutis TE, Greves HM, Lautenbach E, Bilker WB, Coffin SE. Risk factors for disseminated candidiasis in children with candidemia. *Pediatr Infect Dis J* 2004 Jul;23(7):635-641.

- (62) Peman J, Zaragoza R. Current diagnostic approaches to invasive candidiasis in critical care settings. *Mycoses* 2010 Sep;53(5):424-433.
- (63) Alexander BD, Pfaller MA. Contemporary tools for the diagnosis and management of invasive mycoses. *Clinical infectious diseases*. 2006 Aug 1;43 (S)15-27.
- (64) Posteraro B, De Pascale G, Tumbarello M, Torelli R, Pennisi MA, Bello G, et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1-->3)-beta-D-glucan assay, Candida score, and colonization index. *Crit Care* 2011;15(5):R249.
- (65) Kimura Y, Nakao A, Tamura H, Tanaka S, Takagi H. Clinical and experimental studies of the limulus test after digestive surgery. *Surg Today* 1995;25(9):790-794.
- (66) Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. *Clin Diagn Lab Immunol* 2003 Sep;10(5):882-885.
- (67) Vijayakumar R, Giri S, Kindo AJ. Molecular species identification of *Candida* from blood samples of intensive care unit patients by polymerase chain reaction - restricted fragment length polymorphism. *J Lab Physicians* 2012 Jan;4(1):1-4.
- (68) Storm W. Use of thrombocytopenia for the early identification of sepsis in critically ill newborns. *Acta Paediatrica Acad Sci Hung* 1982;23:349-355.
- (69) Deeb MM, Ellahony MD, Zahran AW. Platelets and sepsis in preterm neonates: Is there an organism-specific response? *Journal of American Science* 2012;8(4):76-82.

(70) Guida JD, Kunig AM, Leef KH, McKenzie SE, Paul DA. Platelet count and sepsis in very low birth weight neonates: is there an organism-specific response? *Pediatrics* 2003 Jun;111(6 Pt 1):1411-1415.

(71) Bhat MA, Bhat JI, Kawoosa MS, Ahmad SM, Ali SW. Organism-specific platelet response and factors affecting survival in thrombocytopenic very low birth weight babies with sepsis. *J Perinatol* 2009 Oct;29(10):702-708.

(72) Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. *Clin Infect Dis* 2004 Jan 15;38(2):161-189.

(73) Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. *Clin Infect Dis* 2006 Oct 15;43(8):1060-1068.

(74) Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. *Drugs* 2013 Jun;73(9):919-934.

(75) Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. *Clin Infect Dis* 2003 Sep 1;37(5):634-643.

(76) Zomorodian K, Rahimi MJ, Pakshir K, Motamedi M, Ghiasi MR, Rezashah H. Determination of antifungal susceptibility patterns among the clinical isolates of *Candida* species. *J Glob Infect Dis* 2011 Oct;3(4):357-360.

- (77) Chapman SW, Sullivan DC, Cleary JD. In search of the holy grail of antifungal therapy. *Trans Am Clin Climatol Assoc* 2008;119:197-215.
- (78) Chapman RL. Prevention and treatment of *Candida* infections in neonates. *Semin Perinatol* 2007 Feb;31(1):39-46.
- (79) Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. *Clin Infect Dis* 2006 Oct 15;43(8):1060-1068.
- (80) Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. *N Engl J Med* 2002 Dec 19;347(25):2020-2029.
- (81) Gonzalez de Molina FJ, Leon C, Ruiz-Santana S, Saavedra P, CAVA I Study Group. Assessment of candidemia-attributable mortality in critically ill patients using propensity score matching analysis. *Crit Care* 2012 Jun 14;16(3):R105.
- (82) Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. *Clin Infect Dis* 2003 Nov 1;37(9):1172-1177.
- (83) Marriott DJ, Playford EG, Chen S, Slavin M, Nguyen Q, Ellis D, et al. Determinants of mortality in non-neutropenic ICU patients with candidaemia. *Crit Care* 2009;13(4):R115.

- (84) Levy I, Rubin LG, Vasishtha S, Tucci V, Sood SK. Emergence of *Candida parapsilosis* as the predominant species causing candidemia in children. *Clin Infect Dis* 1998 May;26(5):1086-1088.
- (85) Motta FA, Dalla-Costa LM, Muro MD, Cardoso MN, Picharski GL, Jaeger G, et al. Risk factors for candidemia mortality in hospitalized children. *J Pediatr* 2017 0;93(2):165-171.
- (86) ElGendy F, Hassan F, Khatab A, El-Hendawy G, Saleh N. Study of fungal infections in pediatric intensive care unit in Menoufiya University Hospital. *Menoufia Med J* 2014 1/1;27(1):55-59.
- (87) Agin H, Devrim I, Isguder R, Karaarslan U, Kanik E, Gunay I, et al. Risk factors for candidemia in pediatric intensive care unit patients. *Indian J Pediatr* 2014 Nov;81(11):1158-1162.
- (88) Kumar D, Kumar A, Singh S, Tilak R. Candidemia-induced pediatric sepsis and its association with free radicals, nitric oxide, and cytokine level in host. *J Crit Care* 2015 Apr;30(2):296-303.
- (89) Peman J, Canton E, Linares-Sicilia MJ, Rosello EM, Borrell N, Ruiz-Perez-de-Pipaon MT, et al. Epidemiology and antifungal susceptibility of bloodstream fungal isolates in pediatric patients: a Spanish multicenter prospective survey. *J Clin Microbiol* 2011 Dec;49(12):4158-4163.

(90) Gonzalez GM, Elizondo M, Ayala J. Trends in species distribution and susceptibility of bloodstream isolates of *Candida* collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study. *J Clin Microbiol* 2008 Sep;46(9):2902-2905.

(91) van Asbeck EC, Huang YC, Markham AN, Clemons KV, Stevens DA. *Candida parapsilosis* fungemia in neonates: genotyping results suggest healthcare workers hands as source, and review of published studies. *Mycopathologia* 2007 Dec;164(6):287-293.

(92) Kauffman CA. Fungal infections. *Proc Am Thorac Soc* 2006;3(1):35-40.

(93) Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D, et al. Factors associated with candidemia caused by non-*albicans* *Candida* species versus *Candida albicans* in the intensive care unit. *Clin Infect Dis* 2008 Apr 15;46(8):1206-1213.

(94) Agin H, Devrim I, Isguder R, Karaarslan U, Kanik E, Gunay I, et al. Risk factors for candidemia in pediatric intensive care unit patients. *Indian J Pediatr* 2014 Nov;81(11):1158-1162.

(95) Singhi SC, Reddy TC, Chakrabarti A. Candidemia in a pediatric intensive care unit. *Pediatr Crit Care Med* 2004 Jul;5(4):369-374.

(96) Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. *N Engl J Med* 2000 Dec 28;343(26):1925-1932.

APPENDIX A – REFERENCE VALUES

Age Group	Heart Rate (beats/min)	Respiratory rate (breaths/min)	Leukocyte count (leukocytes x 10 ³ /mm)
0 days to 1 wk	> 180	> 50	> 34
1 wk to 1 mo	> 180	> 40	> 19.5 or < 5
1 mo to 1 yr	> 180	> 34	> 17.5 or < 5
2-5 yrs	> 140	> 22	>15.5 or < 6
6-12 yrs	> 130	> 18	> 13.5 or < 4.5
13 to <18 yrs	> 110	> 14	> 11 or <4.5

APPENDIX B- DATA COLLECTION TOOL

<p><u>STUDY NO:</u></p>	
<p><u>Demographics:</u></p> <p>Age __yr __mo</p> <p>Gender: M <input type="checkbox"/> F <input type="checkbox"/></p> <p>HIV status: Pos <input type="checkbox"/> Neg <input type="checkbox"/></p>	
<p><u>Background:</u></p> <p>DOA: __/__/__</p> <p>Date of Sepsis: __/__/__</p> <p>Pre-ICU major op: Y <input type="checkbox"/> N <input type="checkbox"/></p> <p>Primary Condition: _____</p> <p>Blood culture: _____</p> <p>Sensitivity: _____</p>	<p><u>ICU-related factors:</u></p> <p>CVC: Y <input type="checkbox"/> N <input type="checkbox"/></p> <p>A-line: Y <input type="checkbox"/> N <input type="checkbox"/></p> <p>Chest Drain: Y <input type="checkbox"/> N <input type="checkbox"/></p> <p>Tracheostomy: Y <input type="checkbox"/> N <input type="checkbox"/></p> <p>Antibiotic classes (given \geq24 hrs):</p> <ul style="list-style-type: none"> • Penicillin Y <input type="checkbox"/> N <input type="checkbox"/> • Cephalosporin Y <input type="checkbox"/> N <input type="checkbox"/> • Aminoglyc Y <input type="checkbox"/> N <input type="checkbox"/> • Carbapenem Y <input type="checkbox"/> N <input type="checkbox"/> • Glycopep Y <input type="checkbox"/> N <input type="checkbox"/> • Antifungal Y <input type="checkbox"/> N <input type="checkbox"/> • TMX Y <input type="checkbox"/> N <input type="checkbox"/> • Rifampicin Y <input type="checkbox"/> N <input type="checkbox"/> • Metronidazole Y <input type="checkbox"/> N <input type="checkbox"/> <p>Haemodialysis Y <input type="checkbox"/> N <input type="checkbox"/></p> <p>Peritoneal dialysis Y <input type="checkbox"/> N <input type="checkbox"/></p> <p>Mechanical vent Y <input type="checkbox"/> N <input type="checkbox"/></p> <p>Immunosuppres Y <input type="checkbox"/> N <input type="checkbox"/></p> <p>Multip Transfu Y <input type="checkbox"/> N <input type="checkbox"/></p>

APPENDX C – ETHICS CLEARANCE CERTIFICATE



UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
Division of the Deputy Registrar (Research)

HUMAN RESEARCH ETHICS COMMITTEE (MEDICAL)
R14/49 Dr Seung-Hye Ahn

CLEARANCE CERTIFICATE

M121003

PROJECT

Factors Associated with Nosocomial Fungal Sepsis among Patients in the Paediatric Intensive Care Unit at th CH Baragwanath

Academic Hospital

INVESTIGATORS

Dr Seung-Hye Ahn.

DEPARTMENT

Department of Paediatrics

DATE CONSIDERED

26/10/2012

DECISION OF THE COMMITTEE*

Approved unconditionally

Unless otherwise specified this ethical clearance is valid for 5 years and may be renewed upon application.

DATE 26/10/2012

CHAIRPERSON
(Professor PE Cleaton-Jones)

*Guidelines for written 'informed consent' attached where applicable
cc: Supervisor : Dr KD Naidoo


DECLARATION OF INVESTIGATOR(S)

To be completed in duplicate and **ONE COPY** returned to the Secretary at Room 10004, 10th Floor, Senate House, University.

I/We fully understand the conditions under which I am/we are authorized to carry out the abovementioned research and I/we guarantee to ensure compliance with these conditions. Should any departure to be contemplated from the research procedure as approved I/we undertake to resubmit the protocol to the Committee. **I agree to a completion of a yearly progress report.**

PLEASE QUOTE THE PROTOCOL NUMBER IN ALL ENQUIRIES...

APPENDIX D – HOSPITAL PERMISSION LETTER



GAUTENG PROVINCE

HEALTH
REPUBLIC OF SOUTH AFRICA

MEDICAL ADVISORY COMMITTEE
CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL

PERMISSION TO CONDUCT RESEARCH

Date: 08 November 2012

TITLE OF PROJECT: Factors associated with nosocomial fungal sepsis among patients in the paediatric intensive care unit at the Chris Hani Baragwanath Academic Hospital

UNIVERSITY: Witwatersrand

Principal Investigator: Dr S-H Ahn

Department: Paediatrics

Supervisor (If relevant): Dr K Naidoo

Permission Head Department (where research conducted): Yes

Date of start of proposed study: December 2012

Date of completion of data collection: January 2013

The Medical Advisory Committee recommends that the said research be conducted at Chris Hani Baragwanath Hospital. The CEO /management of Chris Hani Baragwanath Hospital is accordingly informed and the study is subject to:-

- Permission having been granted by the Committee for Research on Human Subjects of the University of the Witwatersrand.
- the Hospital will not incur extra costs as a result of the research being conducted on its patients within the hospital
- the MAC will be informed of any serious adverse events as soon as they occur
- permission is granted for the duration of the Ethics Committee approval.

.....
Recommended
(On behalf of the MAC)
Date: 08 November 2012

.....
Approved/Not Approved
Hospital Management

Date: 12/11/12

APPENDIX E – TURNITIN REPORT

FINAL20161103.docx by Null Null

From FACTORS ASSOCIATED WITH NOSOCOMIAL FUNGAL SEPSIS AMONG
PATIENTS IN THE PAEDIATRIC INTENSIVE CARE UNI

(kb09a520am2XHSyOQw8z1xzb9G793h05L407HP8FiB005DQK5ly0ft96DuBfS2tdp9D
0owMMBzcwLXf52hMbPKI09afHeMTuPHx)

- Processed on 06-Nov-2016 8:55 PM SAST
- ID: 732782433
- Word Count: 10882

Similarity Index: 15%

Similarity by Source

Internet Sources: 14%

Publications: 7%

Student Papers: 3%

Sources:

1 2% match (Internet from 17-Dec-2015)

[http://wiredspace.wits.ac.za/bitstream/handle/10539/12649/KUBAN%20DHASARADH
A%20NAIDOO%209503946F%20-%20MMed%20Research%20Report.pdf](http://wiredspace.wits.ac.za/bitstream/handle/10539/12649/KUBAN%20DHASARADH
A%20NAIDOO%209503946F%20-%20MMed%20Research%20Report.pdf)

2 1% match (Internet from 30-Nov-2012)

<http://cid.oxfordjournals.org/content/51/5/e38.long>

3 < 1% match (Internet from 18-Dec-2014)

<http://www.life->

[worldwide.org/assets/uploads/files/Rodrigues%20Candida%20glabrata%20Eur%20J%20Clin%20Microbiol%20Infect%20Dis%202013\(1\).pdf](http://www.life-worldwide.org/assets/uploads/files/Rodrigues%20Candida%20glabrata%20Eur%20J%20Clin%20Microbiol%20Infect%20Dis%202013(1).pdf)

4 < 1% match (Internet from 12-Oct-2008)

<http://www.nichd.nih.gov/cochrane/Kylat/KYLAT.HTM>

5 < 1% match (Internet from 12-Jan-2014)

<http://beckerinfo.net/JClub/2013/06/04/amphotericin-b-formulations-a-comparative-review-of-efficacy-and-toxicity/>

6 < 1% match (Internet from 18-Oct-2013)

http://www.partnershiptrust.org.uk/files/paperb_annexb.pdf

7 < 1% match (student papers from 23-Aug-2013)

[Submitted to London School of Marketing on 2013-08-23](#)

8 < 1% match (Internet from 30-Oct-2013)

<http://www.science.gov/topicpages/c/candidemia+clinical+outcomes.html>

9 < 1% match (Internet from 03-Jun-2010)

http://www.uptodate.com/patients/content/topic.do?topicKey=~.V7kMFxZrqxjF.&selectedTitle=7~85&source=search_result

10 < 1% match (publications)

"Gauteng Hospital Shambles.", All Africa, May 4 2015 Issue

11 < 1% match (student papers from 30-Apr-2015)

Submitted to University of Leicester on 2015-04-30

12 < 1% match (Internet from 21-Dec-2012)

<http://www.cgionline.ca/cgi/templates/images/RGPEOFullReport.pdf>

13 < 1% match (Internet from 06-Dec-2013)

<http://www.math.umass.edu/~conlon/cs691k/papers/Clarke.pdf>

14 < 1% match (publications)

Joanna Filioti. "Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome", Intensive Care Medicine, 06/22/2007

15 < 1% match (Internet from 17-Jan-2014)

<http://www.hawaii.edu/medicine/pediatrics/pedtext/pedtext5.pdf>

16 < 1% match (Internet from 13-Jun-2015)

<http://www.biomedcentral.com/1741-7015/13/98>

17 < 1% match (Internet from 07-Oct-2010)

<http://www.aspergillus.org.uk/secure/articles/pdfs/04072006a.pdf>

18 < 1% match (student papers from 21-Jul-2016)

[Submitted to Petroleum Research & Development Center on 2016-07-21](#)

19 < 1% match (Internet from 19-Feb-2008)

http://journal.paho.org/?a_ID=173&catID=

20 < 1% match (Internet from 10-Sep-2013)

<http://www.cmpt.ca/critiques/2012/M122-5.pdf>

21 < 1% match (Internet from 25-May-2012)

http://www.jofamericanscience.org/journals/amsci/am0804/011_8248am0804_76_82.pdf

22 < 1% match (Internet from 21-Apr-2010)

<http://hj.diva-portal.org/smash/get/diva2:225168/FULLTEXT01>

23 < 1% match (Internet from 04-Dec-2014)

http://edoc.ub.uni-muenchen.de/16216/1/Klein_Anke-Maria.pdf

24 < 1% match (Internet from 04-Aug-2013)

<http://www.recentmedicalfindings.com/h93w/sepsis-severe-5.html>

25 < 1% match (Internet from 06-Jul-2015)

<http://www.grupogermen.org/pdf/candidas2014.pdf>

26 < 1% match (Internet from 02-Jul-2014)

<http://www.uptodate.com/contents/treatment-of-candidemia-and-invasive-candidiasis-in-adults>

27 < 1% match (publications)

[Sónia Silva. "Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance : Non-Candida albicans Candida species pathogenicity", FEMS Microbiology Reviews, 03/2012](#)

28 < 1% match (student papers from 07-Oct-2009)

[Submitted to Mahidol University on 2009-10-07](#)

29 < 1% match (Internet from 12-Oct-2015)

<http://www.annalsofintensivecare.com/content/1/1/37>

30 < 1% match (Internet from 07-Jan-2007)

<http://www.clinicaltrials.gov/ct/gui/show/NCT00284570?order=40>

31 < 1% match (publications)

Al-Dorzi, Hasan Asiri, Abdulaziz Shimemr. "Impact of empirical antimicrobial therapy on the outcome of critically ill patients with Acinetobact", Annals of Thoracic Medicine, Oct-Dec 2015 Issue

32 < 1% match (student papers from 03-May-2016)

Submitted to University of Northampton on 2016-05-03

33 < 1% match (student papers from 24-Apr-2014)

Submitted to Medizinische Universität Graz on 2014-04-24

34 < 1% match (Internet from 23-Feb-2016)

<http://bjid.elsevier.es/index.php?estadoItem=S300&idApp=UINPBA00003Y&idiomaItem=en&origen=bjid+&p=watermark&piiItem=S141386701400169X&urlApp=http%3A%2F%2Fwww.bjid.org.br%2F&web=bjid+>

35 < 1% match (Internet from 26-May-2016)

http://repub.eur.nl/pub/11126/080206_Melles,%20Damian%20Christian.pdf

36 < 1% match (Internet from 18-Feb-2010)

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC127692/?tool=pubmed>

37 < 1% match (Internet from 20-Mar-2010)

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374590/>

38 < 1% match (Internet from 20-May-2016)

<http://ccforum.biomedcentral.com/articles/10.1186/s13054-015-1010-x>

39 < 1% match (Internet from 15-Sep-2014)

http://www.education.go.ug/files/downloads/TISSA%20Uganda%20Full%20Report_24%20August%202013%20edited%20version%20moses.pdf

40 < 1% match (publications)

[Sonia Silva. "Biofilms of non-Candida albicans Candida species: quantification, structure and matrix composition", Medical Mycology, 2009](#)

41 < 1% match (Internet from 11-Dec-2015)

<http://femsre.oxfordjournals.org/content/36/2/288>

42 < 1% match (Internet from 18-Jan-2010)

<http://www.chiva.org.uk/health/guidelines/treating-oi>

43 < 1% match (Internet from 20-May-2013)

<http://www.biomedcentral.com/1471-2334/10/28>

44 < 1% match (Internet from 15-Mar-2014)

<http://cdn.intechopen.com/pdfs-wm/27953.pdf>

45 < 1% match (Internet from 10-Mar-2012)

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122766/?tool=pubmed>

46 < 1% match (Internet from 10-Nov-2013)

<http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/infectious-disease/mycoses/>

47 < 1% match (Internet from 07-Mar-2013)

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2043413/>

48 < 1% match (Internet from 17-Feb-2011)

<http://mycology.adelaide.edu.au/downloads/Treatment-IFI.pdf>

49 < 1% match (Internet from 29-Mar-2010)

http://www.ktl.fi/attachments/suomi/julkaisut/julkaisusarja_a/2008/2008a11.pdf

50 < 1% match (Internet from 22-Feb-2015)

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2888324/>

51 < 1% match (Internet from 16-Oct-2016)

<https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-016-1431-4>

52 < 1% match (Internet from 22-Sep-2013)

<http://ccforum.com/content/15/5/R253>

53 < 1% match (Internet from 25-Aug-2015)

<http://onlinelibrary.wiley.com/doi/10.1111/imj.12597/full>

54 < 1% match (Internet from 07-Jul-2015)

http://njcc.nl/sites/default/files/NJCC_05%20binnenwerk_06.pdf

55 < 1% match (Internet from 04-Jan-2010)

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC85117/>

56 < 1% match (Internet from 23-Dec-2014)

<http://www.idchula.org/wp-content/uploads/2012/05/Emerging-opportunistic-yeast-infections.pdf>

57 < 1% match (Internet from 15-May-2015)

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122653/>

58 < 1% match (Internet from 26-Feb-2016)

http://www.trialsjournal.com/imedia/1620180881110378_manuscript.pdf

59 < 1% match (Internet from 25-Jul-2010)

<http://lib.bioinfo.pl/meid:32173>

60 < 1% match (Internet from 30-Oct-2015)

<http://clonerresources.com/cgi-bin/DNAFORM/cDNA/en/FetchPubMed?term=KIT>

61 < 1% match (Internet from 22-Oct-2014)

<http://www.recentmedicalfindings.com/g0n3/lung-diseases-fungal-5.html>

62 < 1% match (Internet from 15-Oct-2015)

<http://www.biomedcentral.com/1471-2334/10/292>

63 < 1% match (Internet from 29-Jul-2010)

<http://ccforum.com/content/10/2/R61>

64 < 1% match (Internet from 29-Jun-2014)

<http://repositorium.sdum.uminho.pt/bitstream/1822/11196/1/Tese.pdf>

65 < 1% match (Internet from 26-Aug-2014)

<http://repositorium.sdum.uminho.pt/bitstream/1822/27661/1/Ant%c3%b3nio%20Andr%c3%a9%20de%20Sousa%20Moreira.pdf>

66 < 1% match (Internet from 07-Nov-2014)

<http://www.ambulance.ge/uploads/files/Yearbook%20of%20Intensive%20Care%20and%20Emergency%20Medicine%20Annual%20volumes%202009.pdf>

67 < 1% match (Internet from 18-Nov-2014)

http://etd.uum.edu.my/4040/2/s814579_abstract.pdf

68 < 1% match (Internet from 27-Oct-2010)

<http://advancesinsepsis.com/pdfs/4406.pdf>

69 < 1% match (Internet from 31-Oct-2014)

http://www.tipharma.com/fileadmin/user_upload/Theses/PDF/Theo_Plantinga_D1-101.pdf

70 < 1% match (Internet from 24-Jul-2012)

<http://jmat.mat.or.th/index.php/jmat/article/viewfile/1138/1103>

71 < 1% match (Internet from 19-Apr-2016)

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570155/>

72 < 1% match (Internet from 01-Sep-2015)

http://www.academicjournals.org/article/article1380027510_Dabas.pdf

73 < 1% match (Internet from 28-Oct-2014)

<http://www.repository.up.ac.za/bitstream/handle/2263/24164/Complete.pdf?>

74 < 1% match (Internet from 12-Jun-2014)

<http://www.hst.org.za/uploads/files/sahr2006.pdf>

75 < 1% match (Internet from 30-Jan-2016)

<https://addi.ehu.es/bitstream/10810/11597/1/1471-2334-11-60.pdf>

76 < 1% match (Internet from 06-Jun-2008)

http://www.ngc.gov/summary/summary.aspx?doc_id=4545&nbr=003359&string=%22br east+pain%22

77 < 1% match (Internet from 08-Jul-2008)

http://www.nccn.org/professionals/physician_gls/PDF/fever.pdf

78 < 1% match (Internet from 24-Nov-2009)

<http://pediatrics.aappublications.org/cgi/content/full/111/6/1411>

79 < 1% match (Internet from 24-Oct-2010)

<http://aem.asm.org/cgi/content/full/73/6/1697>

80 < 1% match (Internet from 01-Oct-2015)

<http://www.jidc.org/index.php/journal/article/download/24820467/1067>

81 < 1% match (Internet from 17-Oct-2008)

<http://jcm.asm.org/cgi/content/full/36/7/1886>

82 < 1% match (Internet from 27-May-2016)

http://repub.eur.nl/pub/14316/081008_Emons,%20Marieke.pdf

83

< 1% match (Internet from 02-Dec-2009)

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC193887/?amp=&tool=pubmed>

84 < 1% match (Internet from 12-May-2016)

<http://icmjournal.esicm.org/Journals/abstract.html?doi=10.1007%2Fs00134-013-3109-3>

85 < 1% match (Internet from 21-Jun-2016)

<http://www.ijmm.org/article.asp?issn=0255->

[0857;year=2007;volume=25;issue=4;spage=405;epage=407;aulast=Shivaprakasha](http://www.ijmm.org/article.asp?issn=0255-0857;year=2007;volume=25;issue=4;spage=405;epage=407;aulast=Shivaprakasha)

86 < 1% match (Internet from 08-Jan-2007)

<http://emedicine.com/MED/topic680.htm>

87 < 1% match (Internet from 23-Mar-2010)

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC104549/>

88 < 1% match (Internet from 19-Dec-2015)

<http://pm.microbiology.pl/web/archiwum/vol5122012127.pdf>

89 < 1% match (Internet from 04-Feb-2016)

<http://www.sciedu.ca/journal/index.php/jhm/article/download/1464/1029>

90 < 1% match (Internet from 01-Dec-2013)

http://wwwnc.cdc.gov/eid/article/19/2/12-0971_article.htm

91 < 1% match (publications)

Tabl , Hala Abd El-Mageed | Saeed , Amal M. | Abed , Neveen Tawfik. "(1-3)- β -D-Glucan in Neonatal Candidemia and its Reactivity with Bacterial Blood Stream Infection \\ Egyptian Journal of Medical Microbiology .- 2012 , Vol. 21 , No. 4 , pp. 69 - 78.", The Egyptian Society of Medical Microbiology, 2012.

92 < 1% match (publications)

Joshua Perlroth. "Nosocomial fungal infections: epidemiology, diagnosis, and treatment", Medical Mycology, 6/2007

93 < 1% match (publications)

Jordan, Iolanda, Monica Balaguer, José-Domingo López-Castilla, Sylvia Belda, Cristina Shuffelman, Maria-Angeles Garcia-Teresa, Paula Madurga, Jose-Carlos Flores-Gonzalez, Paloma Anguita, and Lorenzo Aguilar. "Per-Species Risk Factors and Predictors of Invasive Candida Infections in Patients Admitted to Pediatric Intensive Care Units : Development of ERICAP Scoring Systems", The Pediatric Infectious Disease Journal, 2014.

94 < 1% match (publications)

Soltysiak, Jolanta Warzywoda, Alfred Kocinski, Bartlomiej Ostalska-Nowicka, Danuta Benedyk, Anna Sil. "Citrate anticoagulation for continuous renal replacement therapy in small children.(ORIGINAL ARTICLE", Pediatric Nephrology, March 2014 Issue

95 < 1% match (publications)

Zaoutis, Theoklis E., Priya A. Prasad, A. Russell Localio, Susan E. Coffin, Louis M. Bell, Thomas J. Walsh, and Robert Gross. "Risk Factors and Predictors for Candidemia in Pediatric Intensive Care Unit Patients: Implications for Prevention", Clinical Infectious Diseases, 2010.

96 < 1% match (publications)

Sardi, J. C. O., L. Scorzoni, T. Bernardi, A. M. Fusco-Almeida, and M. J. S. Mendes Giannini. "Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options", Journal of Medical Microbiology, 2012.

97 < 1% match (publications)

Mustafa Hacimustafaoglu. "Candida infections in non-neutropenic children after the neonatal period", Expert Review of Anti-infective Therapy, 10/2011

98 < 1% match (publications)

D. Trofa. "Candida parapsilosis, an Emerging Fungal Pathogen", Clinical Microbiology Reviews, 10/01/2008

99 < 1% match (publications)

Makhado, N. A.; Ismail, F.; Dangor, Y.; Chephe, T. J. H.; Hoosen, A. A. and Nchabeleng, M.. "Antifungal susceptibility profile of yeast isolates from sterile sites at a tertiary hospital in South Africa", Southern African Journal of Epidemiology & Infection, 2014.

100 < 1% match (publications)

Garbino, Jorge, Lydia Markham, Raimonda Matulionyte, Vincent Rives, and Daniel Lew. "Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes", Scandinavian Journal of Infectious Diseases, 2006.